Original title: Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease 12-Month Results From the IN.PACT SFA Randomized Trial. Reference: Gunnar Tepe et al. Circulation. 2015;131:495-502. This interesting study randomly selected 331 patients with intermittent claudication or ischemic rest pain due to stenosis of the superficial femoral artery or...
Original title: Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatmentof De Novo Lesions in the Superficial Femoral Artery. The GAIA Study. Reference: Martin Werner et al. J Am Coll Cardiol Intv 2014;7:305–12. The aim of this study was to assess the safety and efficacy of the biodegradable stent Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Japan) in...
Original title: Patient radiation exposure during percutaneous endovascular revascularization of the lower extremity. Reference: Einat Segal et al. Journal of Vascular Surgery. Article in press. Percutaneous endovascular revascularization is emerging as the first line treatment for peripheral artery disease for both intermittent claudication and chronic critical limb ischemia. Radiation doses for these interventions, usually prolonged, have not been...
Original title: Treatment of Complex Atherosclerotic PoplitealArtery Disease With a New Self-Expanding Interwoven Nitinol Stent. 12-Month Results of the Leipzig SUPERA Popliteal Artery Stent Registry. Reference: Dierk Scheinert, et al. J Am Coll Cardiol Intv 2013;6:65–71 Currently, peripheral angioplasty (PTA) of the popliteal artery is a real challenge since stent implantation is controversial and the outcome of balloon...
Aortic stenosis is an increasingly common valvulopathy because people are living longer now. A present, the main treatment consists of surgical (SAVR) or transcatheter aortic valve replacement. (TAVR). One of the main challenges of this disease is its progression. The European guidelines recommend Doppler echocardiograms every 2 to 3 years for mild cases, mildly calcified,...
For years, treating dyslipidemia mainly focused on reducing LDL cholesterol (LDL-C) with statins, which had shown benefits in reducing atherosclerotic cardiovascular disease (ASCVD). Lipoprotein(a) [Lp(a)] is a form of apoB-containing lipoprotein bound to a hydrophilic, highly glycosylated protein called apolipoprotein(a) [apo(a)]. Circulating levels of Lp(a) are genetically determined, and are hardly affected by eating habits...
Advanced stages of peripheral artery disease cause significant limitations in patients, such as critical limb ischemia (CLI), which manifests with resting pain and gangrene or ulcers of difficult resolution. Uncontrolled progression of this pathology might lead to major amputation, reduced life expectancy and increased healthcare costs. Prior research on infrapopliteal territory have shown contradicting results....
Percutaneous treatment of chronic total occlusions has increase, and has become a a more habitual therapeutic challenge. However, there is limited information on distal vessel quality and its association with outcomes and techniques. This variable appears to be excluded form CTO scores, except for the RECHARGE (REgistry of CrossBoss and Hybrid procedures in FrAnce, the...
Among patients undergoing percutaneous coronary intervention (PCI), there is a need for risk stratification for successful planning and post procedural management. Risk stratification is paramount for effective decision making. For a long time, the SYNTAX score has been the preferred tool for complex PCI patient risk assessment. However, it has important limitations, such as inter-observer...
Below, we share March’s most read scientific abstracts in interventional cardiology at solaci.org. ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable...